Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Milestone Scientific reports revenue growth and strategic partnerships in Q3

Milestone Scientific shows promising revenue growth and operational improvements in Q3 2024, driven by strong Dental division performance and international sales.
Strategic partnerships and a solid financial position enhance market reach and provide a foundation for future growth.
Challenges include reducing net losses, driving market adoption of CompuFlo, and navigating Medicare coverage expansion, while opportunities exist in reimbursement initiatives and market expansion post-approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Milestone Scientific Inc. (NYSE:MLSS ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants David Waldman - Crescendo Communications, Investor Relations Arjan Haverhals - Chief Executive Officer and President Keisha Harcum - Vice President, Finance Conference Call Participants Nick Sherwood - Maxim Group. Bruce Jackson - Benchmark Company Operator Good morning, everyone.

Milestone Scientific Inc. (MLSS) Q3 2024 Earnings Call Transcript

Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024.

Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition.

Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 15th, 2024, to discuss the company's financial results for the third quarter ended September 30, 2024, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules Third Quarter 2024 Financial Results and Business Update Conference Call

Recent Medicare Price Assignment Driving Increased Access to CompuFlo Milestone Scientific to Attend New York and New Jersey Pain Medicine Congress 2024 ROSELAND, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial rollout of its CompuFlo® Epidural System at Hudson Specialty Care, led by renowned physician Dr. Elbaz.

Milestone Scientific Expands Commercial Rollout of the CompuFlo® Epidural System with Esteemed Pain Management Physician Dr. Elbaz at Hudson Specialty Care

Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics

Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at iHeal Pain Center Following Medicare Price Assignment

Milestone Scientific Inc. (NYSE:MLSS ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants David Waldman - Investor Relations, Crescendo Communications Arjan Haverhals - Chief Executive Officer Keisha Harcum - Vice President, Finance Conference Call Participants Anthony Vendetti - The Maxim Group Operator Good morning, and welcome to the Milestone Scientific Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode and we will open for questions following the presentation.

Milestone Scientific Inc. (MLSS) Q2 2024 Earnings Call Transcript

Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024.

Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024

ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, August 15th, 2024, to discuss the company's financial results for the second quarter ended June 30, 2024, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a strategic partnership with Axial Biologics, a premier medical device company with a vast distribution network. Under the agreement, Axial Biologics will serve as the distributor of Milestone Scientific's CompuFlo® Epidural System in New Jersey, Texas, and Florida.

Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida

ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced receipt of multiple Notices of Allowance (NOA) for essential patent applications in both the U.S. and Europe.

Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe

ROSELAND, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Novitas Solutions, Inc. (Novitas), a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the Company's CompuFlo® Epidural System under the American Medical Association's (AMA) technology-specific Category III CPT® code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure).

Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware

Brazil is the 9th largest economy in the world with more than  21 million people suffering from chronic back pain

Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil

Milestone Scientific Inc. (MLSS) Q1 2024 Earnings Call Transcript

Sales through new online portal increase 31% over the same period last year Gross margin for the first quarter of 2024 increases to 74.5% from 72.7% for the same period last year Reports steady progress on reimbursement strategy for the CompuFlo® Epidural System ROSELAND, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the first quarter ended March 31, 2024.

Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024

ROSELAND, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 16th, 2024, to discuss the company's financial results for the first quarter ended March 31, 2024, as well as the company's corporate progress and other developments.

Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call

Milestone Scientific Inc. (MLSS) Q4 2023 Earnings Call Transcript

Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company's financial results for 2023, as well as the company's corporate progress and other developments

Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call

Follows successful evaluation by Omaha Pain Physicians' founder and medical director, Dr. Matthew Stottle, reporting 100% success Follows successful evaluation by Omaha Pain Physicians' founder and medical director, Dr. Matthew Stottle, reporting 100% success

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians

ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio, a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin.

Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio

ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA) with Maine Dental Group, a premier group of 21 dental practices across the northeastern United States.

Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast

Reports initial reimbursements of CompuFlo® by commercial payors and Medicare Reports initial reimbursements of CompuFlo® by commercial payors and Medicare

Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update

New York, December 27, 2023 – Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133 foreign patents.

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

ROSELAND, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of its previously announced underwritten public offering of 4,765,000 shares of its common stock at a public offering price of $0.63 per share (the “Offering”). Gross proceeds before deducting underwriting discounts, commissions and other Offering expenses were approximately $3.0 million.

News for Milestone Scientific Stock (MLSS)